Inc. took a nosedive today, dropping around 20% after the company announced results from the Phase 2 study of its ...

Intellia Therapeutics has taken another step toward its goal of winning the first approval for an in vivo CRISPR therapy, ...

Newly published data show the therapy reduced the rate of swelling attacks in people with hereditary angioedema, but didn't ...

For adults with hereditary angioedema, the in vivo gene-editing therapy NTLA-2002, which is based on clustered regul ...

Intellia Therapeutics' Phase 2 data shows NTLA-2002, a CRISPR gene therapy, reduced hereditary angioedema attack rates by up to 81%, with complete responses.

Intellia Therapeutics (NASDAQ:NTLA) fell ~9% in the pre-market on Thursday after the biotech announced data from an ongoing ...

JonesTrading analyst Debanjana Chatterjee has assigned their bullish stance on NTLA stock, giving a Buy rating on October 16. Debanjana ...

After disclosing data from a Phase 2 trial for its CRISpen-based medication, NTLA-2002, covering hereditary angioedema (HAE), ...

NTLA-2002 is a single-dose treatment designed to prevent potentially life-threatening swelling attacks in people with hereditary angioedema (HAE) NTLA-2002 is Intellia’s second in vivo candidate ...

Investor webcast to review the NTLA-2002 Phase 2 data is now planned for Thursday, October 24 at 8:30 a.m. ET CAMBRIDGE, Mass ...

BMO Capital analyst Kostas Biliouris maintained a Buy rating on Intellia Therapeutics (NTLA – Research Report) today and set a price ...

Intellia Therapeutics, Inc. NTLA announced that it has initiated the pivotal phase III HAELO study evaluating NTLA-2002 for the treatment of hereditary angioedema (HAE). The global double-blind ...